Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd. operates as a clinical stage biotechnology company. It engages in the research and development of biotechnological and pharmaceutical products. The firm specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple Sclerosis, Crohn's disease and KRAS+ NSCLC. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. It specializes in developing transformative therapies for neurodegenerative and lung diseases. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) this week announced positive research findings showing the anti-inflammatory potential of the company's nasal anti-CD3 antibody foralumab when used in combination with semaglutide, a GLP-1 agonist marketed as Ozempic and Wegovy. CEO Ivor Elrifi joined Proactive to discuss the findings.

Tiziana Life Sciences CEO discusses foralumab potential to enhance Ozempic - ICYMI

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will participate in the upcoming BIO-Europe 2024 conference in Stockholm. The event will allow Tiziana to engage with industry leaders, potential collaborators, and investors, emphasizing its recent clinical advancements, particularly data from its combination study involving Ozempic, a GLP-1 agonist.

Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference's partnering meetings, Tiziana will engage with industry leaders, potential collaborators, and investors to discuss recent clinical progress, including data from its combination study involving Ozempic, a GLP-1 agonist.

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has secured up to $10 million in funding through a registered direct offering. The offering includes an initial investment of approximately $5 million raised through the sale of 5,263,158 common shares at $0.95 each, with closing expected around November 1, 2024, The agreement also includes an option allowing the investor to acquire an additional 5,263,158 shares at the same price within 75 days, potentially bringing in another $5 million.

Tiziana Life Sciences secures funding to advance development of MS and Alzheimer's therapy

Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported positive results from a preclinical study evaluating the combination of its lead development candidate intranasal foralumab and semaglutide, which is marketed by Novo Nordisk (NYSE:NVO) under the brand names Ozempic and Wegovy. The study demonstrated that this combination effectively promotes liver homeostasis and reduces inflammation in preclinical models of diet-induced obesity.

Tiziana Life Sciences reports promising preclinical results for novel combination therapy targeting obesity

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has secured a $4 million grant from the National Institutes of Health (NIH) to advance research of nasal anti-CD3 as a treatment for Alzheimer's disease. The company has been developing a fully human, anti-CD3 monoclonal antibody called intranasal foramulab, which has demonstrated a favorable safety profile and clinical response in studies to date.

Tiziana Life Sciences awarded $4M to advance Alzheimer's disease research

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the appointment of Ivor Elrifi as its CEO, replacing acting CEO Gabriele Cerrone who will remain in his role as executive chairman of the board. The company highlighted that Elfiri previously served as the global head of the Patent Group at Cooley since 2014, and before that, he led the Patents division at Mintz Levin from 1999 to 2014.

Tiziana Life Sciences names new chief executive

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the appointment of Ivor Elrifi as its Chief Executive Officer (CEO), effective immediately.

Tiziana Life Sciences Appoints New Chief Executive Officer

Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares moved higher after the biotechnology firm revealed the US Food and Drug Administration (FDA) has granted Fast Track designation to its intranasal formulation of foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis.   The FDA's Fast Track designation is intended to support the development of and review of drugs that address an unmet medical need.

Tiziana Life Sciences secures FDA Fast Track status for MS therapy intranasal foralumab

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its intranasal formulation of foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS).

Tiziana Life Sciences Granted FDA Fast Track Designation

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced it has received non-dilutive funding of $3.4 million which will be used to advance its investigation therapy foralumab. The company highlighted that foralumab is the only fully human anti-CD3 monoclonal antibody (mAb), which binds to the T cell receptor and dampens inflammation by modulating T cell function, therefore suppressing effector features in multiple immune cell subsets.

Tiziana Life Sciences secures $3.4M in non-dilutive funding

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to active neuroinflammatory processes today announced that it had received non-dilutive funding of $3.4 million and issued a corporate update video available here.

Tiziana Receives $3.4 Million in Non-Dilutive Funding

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has won approval from the US Food and Drug Administration under an Expanded Access IND to dose its first patient with moderate Alzheimer's disease with its investigational therapeutic intranasal foralumab. Expanded access INDs allow patients to gain access to investigational drugs, biologics and medical devices to treat serious diseases and conditions for which there are no comparable or satisfactory therapy options outside of clinical trials, the biopharmaceutical company said.

Tiziana Life Sciences secures FDA approval to dose first patient with moderate Alzheimer's with investigational therapy

NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration (FDA) has allowed intranasal foralumab to be used under an Expanded Access (EA) IND in its first patient with moderate Alzheimer's disease.

Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with Foralumab

Tiziana Life Sciences Ltd (NASDAQ:TLSA), said it is seeking Fast Track Designation approval from the US Food and Drug Administration (FDA) for its intranasal foralumab therapy to treat non-active, secondary-progressive multiple sclerosis (na-SPMS). Foralumab, a fully human anti-CD3 monoclonal antibody, has demonstrated the ability to induce T regulatory cell production when administered intranasally.

Tiziana Life Sciences seeks FDA Fast Track Designation for foralumab in MS treatment

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled encouraing results from patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS) enrolled in its Expanded Access Program who have been receiving its drug asset foralumab for at least six months. The company is developing foralumab, the only fully human anti-CD3 mAb, which has demonstrated a favorable safety profile and clinical response in patients in studies to date.

Tiziana Life Sciences reports qualitative improvement in MS patients treated with lead asset

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it along with its research partners at Mass General Hospital have been invited to apply for a prestigious grant from the ALS Association to fund a clinical trial evaluating its asset intranasal foralumab. The company said the grant is offered as part of the Hoffman ALS Clinical Trial Awards Program, which helps develop new and improved therapies for ALS by supporting early-stage clinical trials.

Tiziana Life Sciences seeks funding from ALS Association for intranasal foralumab trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the Chairman of its Scientific Advisory Board, Howard L  Weiner, is to receive the “Giants of MS” award. The award ceremony will be held on May 30, 2024, during the Consortium of Multiple Sclerosis Centers annual meeting in Nashville, Tennessee.

Tiziana Life Sciences' chief advisor to receive "Giants of MS" award

NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Howard L. Weiner, M.D., Chairman of Tiziana's Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham healthcare system, is being honored with the prestigious “Giants of MS” award for his outstanding contributions in the area of multiple sclerosis (MS) research. The award ceremony will take place on May 30, 2024 at the Consortium of Multiple Sclerosis Centers annual meeting being held in Nashville, Tennessee.

Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has requested its multiple sclerosis treatment be granted orphan drug designation by the Food and Drug Administration (FDA). Tiziana's intranasal foralumab would be the first to receive the designation for non-active secondary progressive multiple sclerosis were it to be approved, the biotechnology firm said on Monday.

Tiziana eyes orphan drug designation for multiple sclerosis treatment

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it has submitted an FDA request to obtain Orphan Drug Designation for intranasal foralumab for the treatment of non-active secondary progressive Multiple Sclerosis (na-SPMS). This request would make foralumab the first therapy for na-SPMS to receive Orphan Drug Designation. Our request is supported by clinical and non-clinical evidence of Foralumab's effectiveness in na-SPMS. The prevalence estimates, in part, are supported from the Brigham & Women's Hospital, Boston, Massachusetts, longitudinal study, the CLIMB data of which allowed the estimate of na-SPMS in the population.

Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled new neuroimaging data which shows its investigational drug intranasal foralumab improved White Matter Z-scores in patients with non-secondary progressive Multiple Sclerosis (na-SPMS).   White Matter Z-scores are a statistical measure in neuroimaging studies used to assess the integrity or abnormalities of structures in the brain.

Tiziana Life Sciences unveils positive neuroimaging data for foralumab in MS patients

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced for the first time, quantitative data showing improvement in White Matter Z-scores measured from PET images taken at 3 months in nasal foralumab treated patients with non-active secondary progressive multiple sclerosis (na-SPMS). White Matter Z-scores are a statistical measure used in neuroimaging studies to assess the integrity or abnormalities in structures of the brain.

Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has been approved by the US Food and Drug Administration to expand patient enrollment in its non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access Program. The company said it will expand the program, which is evaluating its investigative therapeutic intranasal foralumab, from 10 patients to 30.

News for Tiziana Life Sciences Ltd Stock (TLSA)